MacroGenics Strikes Second Oncology Partnership With Servier
This article was originally published in The Pink Sheet Daily
Executive Summary
The French pharma paid $20 million up-front for rights to option three preclinical programs, including drugs targeting both solid and liquid-tumor cancers.
You may also be interested in...
Biopharma Dealmaking Quarterly Statistics, Q3 2012
Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.
Deals Of The Week: Sanofi/Genfar, Janssen/Astellas, Evotec/Bayer
It was an important week for Celgene, which made two cancer deals while producing data that help validate its $2.9 billion buyout of Abraxane.
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).